MedicaidPrior AuthLow impact
Poteligeo® (mogamulizumab-kpkc) (New)
Humana·LA · Oncology, Hematology, Dermatology·Medicaid
Effective date
Mar 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicaid Louisiana has established a new prior authorization policy for Poteligeo (mogamulizumab-kpkc), an intravenous cancer treatment for mycosis fungoides or Sézary syndrome. Prior authorization will be required starting March 1, 2026, with specific criteria including relapsed or refractory disease and use as sole systemic therapy.
Action Required
Before March 1, 2026: Billing team must update prior authorization requirements for Poteligeo (mogamulizumab-kpkc) infusions for Louisiana Medicaid patients with mycosis fungoides or Sézary syndrome. Verify patients meet criteria: relapsed/refractory disease and use as sole systemic therapy. Visit www.humana.com/PAL for specific medical billing codes and preauthorization requirements.